Availability of Mifepristone and Misoprostol in Oregon Pharmacies: A Comparison by Rural and Urban Status.

Abortion mifepristone misoprostol pharmacy

Journal

Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361

Informations de publication

Date de publication:
17 May 2024
Historique:
received: 17 01 2024
revised: 17 03 2024
accepted: 14 05 2024
medline: 20 5 2024
pubmed: 20 5 2024
entrez: 19 5 2024
Statut: aheadofprint

Résumé

To evaluate the availability of mifepristone and misoprostol at pharmacies in a state with protective abortion legislation and variation in access by rurality. Using a secret shopper survey, researchers attempted to contact all community pharmacies in Oregon and evaluate their mifepristone and misoprostol provision. Among the 444 pharmacies surveyed, mifepristone was planned at 19.2%. Misoprostol was available at 77.5%, but stocking issues and medication ordering impact access, without significant difference by rurality. Pharmacy engagement and support is key to increasing access to these essential medicines, which may be improved through education and referral programs.

Identifiants

pubmed: 38763275
pii: S0010-7824(24)00163-X
doi: 10.1016/j.contraception.2024.110491
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110491

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Auteurs

Rachel Mnuk (R)

Department of Obstetrics & Gynecology, Oregon Health & Science University. Electronic address: mnuk@ohsu.edu.

Kaitlin Schrote (K)

Center for Reproductive Health Equity, Department of Obstetrics & Gynecology, Oregon Health & Science University.

Bharti Garg (B)

Department of Obstetrics & Gynecology, Oregon Health & Science University.

Uma Doshi (U)

Oregon Health & Science School of Medicine.

Maria I Rodriguez (MI)

Center for Reproductive Health Equity, Department of Obstetrics & Gynecology, Oregon Health & Science University.

Classifications MeSH